Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Gene targeting and localized delivery of anti-neoplastic agents More
Two new compounds having HDAC (histone deacetylase) inhibition capability have shown the effect of inducing re-differentiation of human brain and breast cancer cells both in vitro and in vivo. More
"A comprehensive set of samples in various diseases. The resource consists of DNA samples from 16 diseases (Type I diabetes, Type II diabetes, Asthma, Colorectal Cancer, Breast Cancer, Prostate Cancer, Alzheimer's disease, Parkinson's disease... More
A new class of compounds with pure anti-estrogen activity has been identified. The compounds are structurally unique and possess higher affinity to the human estrogen receptor and exhibit a substantially increased oral bioavailability than faslodex. More
In addition to anti-tumor activity, these compounds have been shown to be potent irreversible inhibitors of P-glycoprotein, a member of the ABC transporter protein family that has a major role in conferring multi-drug resistance. More
Methods and assays which may be used to diagnose and follow the progression of cancers associated with c-Met expression More
These hybrid antibody molecules can be engineered with a variety of small synthetic molecules, and the combination of immunogenic properties results in compounds with powerful target destruction or imaging capabilities. More
Researchers at the University of Edinburgh, led by Professor Peter Sadler, have developed a novel series of platinum prodrugs, which can be activated by light (photoactivated). More
The present invention describes cytotoxic compounds with an intracellular target that can selectively enter tumor cells through specific receptors on the cell surface. More
Two isolate Chinese hamster cell lines useful in screening for chemotherapeutic drugs targeting the pathways. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Adenocarcinoma
- Breast cancer, other
- Ductal carcinoma in situ
- Invasive ductal breast cancer
- Invasive lobular breast cancer
- Lobular carcinoma in situ
- Paget's Disease
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us